Research Study

A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (NHL)
Principal Investigator 
Kevin Song

Overview

Body Locations and Systems 
Immune System and Disorders
Disorders and Conditions 
ClinicalTrials.gov# 
NCT02348216
Status 
Recruiting
Study Start/End 
Jan 20, 2017 to Dec 31, 2027
Locations 
Vancouver General Hospital
Name/Title 
Melanie Lam, Research Coordinator
Phone 
604-875-4111 Ext.22960.
Purpose of Study 

This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in refractory aggressive Non-Hodgkin Lymphoma (NHL).

Eligibility 

Please visit ClinicalTrials.gov for more information.

Disclaimer 

Study Coordinators and Research Nurses cannot give medical advice over the phone. Telephone numbers and email addresses are provided for obtaining additional information on specific research studies only. If you have specific questions which require clinical expertise, please call your primary care physician.